Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E22.22 EPS (ttm)5.91 Insider Own0.05% Shs Outstand2.69B Perf Week-2.28%
Market Cap353.62B Forward P/E16.98 EPS next Y7.74 Insider Trans-12.78% Shs Float2.68B Perf Month-1.06%
Income16.34B PEG3.52 EPS next Q1.80 Inst Own68.10% Short Float0.51% Perf Quarter-3.69%
Sales72.53B P/S4.88 EPS this Y8.30% Inst Trans-0.03% Short Ratio2.54 Perf Half Y4.71%
Book/sh26.72 P/B4.92 EPS next Y7.71% ROA11.30% Target Price137.16 Perf Year9.99%
Cash/sh4.78 P/C27.51 EPS next 5Y6.32% ROE22.90% 52W Range109.32 - 137.08 Perf YTD14.04%
Dividend3.36 P/FCF40.04 EPS past 5Y11.20% ROI17.00% 52W High-4.15% Beta0.78
Dividend %2.56% Quick Ratio1.00 Sales past 5Y2.00% Gross Margin69.40% 52W Low20.19% ATR1.69
Employees126400 Current Ratio1.30 Sales Q/Q1.90% Oper. Margin27.50% RSI (14)45.25 Volatility1.30% 1.16%
OptionableYes Debt/Eq0.48 EPS Q/Q-2.40% Profit Margin22.50% Rel Volume0.80 Prev Close131.75
ShortableYes LT Debt/Eq0.38 EarningsOct 17 BMO Payout53.80% Avg Volume5.41M Price131.39
Recom2.60 SMA20-0.81% SMA50-1.09% SMA2004.79% Volume4,329,390 Change-0.27%
Sep-20-17Downgrade Goldman Neutral → Sell $125 → $130
Jul-21-17Downgrade BTIG Research Neutral → Sell $110
Jul-21-17Downgrade Alembic Global Advisors Neutral → Underweight
Jul-20-17Resumed Credit Suisse Outperform $148
Jul-05-17Reiterated Morgan Stanley Overweight $135 → $140
May-18-17Reiterated Stifel Hold $124 → $128
May-15-17Upgrade JP Morgan Neutral → Overweight
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
Sep-24-17 09:18AM  Could This Be Warren Buffett's Greatest Weakness? Motley Fool
Sep-22-17 05:19PM  FDA declines to approve J&J arthritis drug sirukumab Reuters
04:33PM  U.S. FDA rejects J&J's arthritis drug Reuters
04:18PM  Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson Motley Fool
12:19PM  Johnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : September 22, 2017 Capital Cube
09:07AM  What Pfizers Valuation Changes after 2Q17 Tell Us Market Realist
08:59AM  Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com Zacks
08:42AM  Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update Zacks
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Sep-21-17 10:49PM  J&J Was Alerted to Risk of Asbestos in Talc in 70s, Files Show Bloomberg
04:00PM  Johnson & Johnson : JNJ-US: Dividend Analysis : August 29th, 2017 (record date) : By the numbers : September 21, 2017 Capital Cube
02:49PM  J&J? Its Time to Sell on Valuation: Goldman Sachs Investopedia
01:00PM  Research Shows That Canadian Military Servicemembers and First Responders Struggle to Get Support for Their Own Health Needs CNW Group
10:55AM  Karyopharm's Liposarcoma Candidate Superior in Phase II Study Zacks
10:25AM  Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake Zacks
09:35AM  Pharma giants' to clash in court over biosimilar product dispute American City Business Journals
09:15AM  3 Stocks to Help You Make Money in Retirement Motley Fool
09:08AM  A Venerable Vanguard Dividend ETF Benzinga
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
06:48AM  This squabble between two big drugmakers could have major implications for the U.S. health care system MarketWatch
12:44AM  [$$] The Murky World of Drug Rebates Gets Airing in Lawsuit The Wall Street Journal
12:43AM  [$$] Pfizer Alleges J&J Thwarted Competition to Remicade, in Legal Test of Biotech-Drug Copies The Wall Street Journal
12:41AM  PRESS DIGEST - Wall Street Journal - Sept 21 Reuters
Sep-20-17 08:46PM  Pfizer and Johnson & Johnson's Brewing Brawl Gets Real Motley Fool
07:09PM  Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners TheStreet.com
06:46PM  [$$] Pfizer Alleges J&J Thwarted Competition to Remicade, in Legal Test of Biotech-Drug Copies The Wall Street Journal
04:47PM  Top Research Reports for Northrop Grumman, BNY Mellon & Celgene Zacks
03:46PM  Pfizer is taking its fight with J&J over a blockbuster drug to court Business Insider
03:42PM  [$$] Pfizer takes on J&J with antitrust lawsuit Financial Times
03:23PM  Pfizer files suit against J&J over Remicade contracts Reuters
02:18PM  J&J: You Can Only Stretch That Valuation So Far Barrons.com
02:17PM  [$$] Murky World of Drug Rebates Gets Airing in Lawsuit The Wall Street Journal
01:46PM  Goldman cuts one key Dow component to a "sell" CNBC Videos
01:45PM  Cramer: Goldman's Downgrade Of J&J Is 'Questionable' TheStreet.com
01:25PM  Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell' TheStreet.com
11:49AM  Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers Benzinga
10:18AM  Pfizer files suit against J&J over Remicade contracts Reuters
09:11AM  Sell Johnson & Johnson because of its 'stretched' valuation: Goldman CNBC
08:46AM  Morning Movers: General Mills Slumps, Johnson & Johnson Slips, American Airlines Gains Barrons.com
08:01AM  3 Dividend Stocks That Should Pay You the Rest of Your Life Motley Fool
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
06:32AM  Why Exelixis Wouldn't Be a Warren Buffett Stock Motley Fool
Sep-19-17 06:14PM  [$$] Johnson & Johnson Acquires Contact Lens Service Sightbox The Wall Street Journal
11:58AM  The only thing Trump is doing to end the opioid crisis rewards the companies that started it Business Insider
10:37AM  Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia Zacks
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Sep-18-17 04:32PM  Portland's Sightbox sold to health care behemoth American City Business Journals
02:21PM  3 Dividend Stocks Ideal for Your Golden Years Motley Fool
12:09PM  My Buy and Sell Ratings on the 20 Largest Stocks GuruFocus.com
10:23AM  Catalyst (CPRX) Focused on Two Lead Pipeline Candidates Zacks
10:15AM  J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU Zacks
10:00AM  Neos Therapeutics ADHD Drug Adzenys Receives Approval in US Zacks
10:00AM  Q2 2017 S&P 500 Buybacks Fall 9.8% from Q1, to $120.1 Billion PR Newswire
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
07:39AM  Abbott Laboratories 375th Consecutive Quarterly Dividend Market Realist
Sep-17-17 12:59PM  3 Stocks to Hold for the Next Century Motley Fool
09:18AM  Don't Make This Huge Mistake With Celgene Motley Fool
08:34AM  10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright Motley Fool
Sep-15-17 05:16PM  The Smartest Move Johnson & Johnson Has Made All Year Motley Fool
04:32PM  [$$] JNJ May Benefit From Celltrion Issues Barrons.com
01:30PM  Ridiculously Weak U.S. Dollar Will Make These 10 Companies Huge Winners TheStreet.com
01:18PM  Why Amgen, Lilly, J&J Are Interested In These Small Biotechs Investor's Business Daily
10:36AM  Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study Zacks
09:57AM  Johnson & Johnson Is Getting Ready for Another Upside Breakout TheStreet.com
08:46AM  Abbotts Amplatzer Device Affirms Reduced Recurrent Stroke Rates Market Realist
08:40AM  European panel backs Janssen's psoriasis drug Reuters
08:15AM  Pfizer Punches Back at Johnson & Johnson in Prostate Cancer Motley Fool
08:04AM  European panel recommends approval of J&J's psoriasis drug Reuters
Sep-14-17 07:50PM  How to spot market rotations CNBC Videos
06:45PM  Cramer's No. 1 rule for spotting market rotations CNBC Videos
06:31PM  ETFs with exposure to Johnson & Johnson : September 14, 2017 Capital Cube
05:15PM  Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results PR Newswire
11:22AM  These party drugs could become the answer for clinically ... CNBC Videos
11:00AM  Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx Zacks
10:01AM  Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod Zacks
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
03:30AM  Astra's Farxiga results may open up type 1 diabetes opportunity Reuters
Sep-13-17 11:29AM  Johnson & Johnson :JNJ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
09:29AM  Integra Divests Assets to Natus, Paves Way for Codman Buyout Zacks
09:00AM  Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies PR Newswire
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Sep-12-17 11:39AM  Achillion's HCV Partnership with J&J Terminated, Stock Falls Zacks
10:09AM  Johnson & Johnson breached its 50 day moving average in a Bullish Manner : JNJ-US : September 12, 2017 Capital Cube
09:14AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy InvestorPlace
09:06AM  Assessing Mercks Immunology and Cardiovascular Franchise in 2Q17 Market Realist
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Sep-11-17 04:30PM  Federated, Carnival, Alphabet climb; Regeneron skids Associated Press
04:30PM  Why Achillion Pharmaceuticals Crashed 22.2% Today Motley Fool
04:12PM  S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears TheStreet.com
01:48PM  Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease TheStreet.com
01:34PM  Low-Volatility ETFs Can Help Investors Ride Out A Market Pullback Barrons.com
09:46AM  Achillion Shares Are Plunging on Termination of Hepatitis C Pact TheStreet.com
08:50AM  Achillion Pharma Slides After Hep C Deal Is Terminated 24/7 Wall St.
08:34AM  Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends CNBC
07:51AM  Early movers: HCI, UVE, HRTG, XL, RE, JNJ, PPC, TEVA, AAPL & more CNBC
Sep-10-17 03:14PM  Johnson & Johnson, 3M and 8 Other Winners From the Ridiculously Weaker Dollar TheStreet.com
07:10AM  2 Dividend Stocks You Can Buy and Hold Forever Motley Fool
Sep-09-17 10:06AM  US Market Indexes Mostly Lower Friday With Losses for the Week GuruFocus.com
Sep-08-17 08:06PM  3 Top Index Funds to Keep You in the Investing Game Motley Fool
03:00PM  Johnson & Johnson, 3M and 8 Other Winners From the Ridiculously Weaker Dollar TheStreet.com
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusExec VP, Chief Scientific OffJul 24Option Exercise72.54102,6927,449,278230,342Jul 26 11:49 AM
Stoffels PaulusExec VP, Chief Scientific OffJul 24Sale133.14102,69213,672,629127,650Jul 26 11:49 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Option Exercise61.7582,5915,099,994226,693Jul 24 11:06 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Sale136.7282,59111,291,478144,102Jul 24 11:06 AM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM